BR112014019825A8 - Glicoengenharia quimioenzimática de anticorpos e fragmentos fc dos mesmos - Google Patents
Glicoengenharia quimioenzimática de anticorpos e fragmentos fc dos mesmosInfo
- Publication number
- BR112014019825A8 BR112014019825A8 BR112014019825A BR112014019825A BR112014019825A8 BR 112014019825 A8 BR112014019825 A8 BR 112014019825A8 BR 112014019825 A BR112014019825 A BR 112014019825A BR 112014019825 A BR112014019825 A BR 112014019825A BR 112014019825 A8 BR112014019825 A8 BR 112014019825A8
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- chemioenzymatic
- glycoengineering
- fragments
- fucosylated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/473—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used alpha-Glycoproteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/005—Glycopeptides, glycoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4725—Proteoglycans, e.g. aggreccan
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01096—Mannosyl-glycoprotein endo-beta-N-acetylglucosaminidase (3.2.1.96)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/46—Streptococcus ; Enterococcus; Lactococcus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
GLICOENGENHARIA QUIMIOENZIMÁTICA DE ANTICORPOS E FRAGMENTOS FC DOS MESMOS. A presente invenção proporciona mutantes Endo-S recombinantes que exibem atividade de hidrólise reduzida e atividade de transglicosilação aumentada para a síntese das glicoproteínas, em que uma desejada oxazolina sialilada ou oxazolina oligossacarideo sintética é adicionada a um aceptor G1cNAc-proteína de núcleo fucosilado ou não fucosilado. Tais mutantes Endo-S recombinantes são úteis para a remodelação de glicosilação eficiente domínio IgG1-Fc para fornecer diferentes glicoformas de anticorpos que portam estruturalmente Fc N-glicanos bem definidos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261597468P | 2012-02-10 | 2012-02-10 | |
US61/597,468 | 2012-02-10 | ||
PCT/US2013/025553 WO2013120066A1 (en) | 2012-02-10 | 2013-02-11 | Chemoenzymatic glycoengineering of antibodies and fc fragments thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112014019825A2 BR112014019825A2 (pt) | 2017-06-20 |
BR112014019825A8 true BR112014019825A8 (pt) | 2017-07-11 |
BR112014019825B1 BR112014019825B1 (pt) | 2021-08-24 |
Family
ID=48948091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112014019825-0A BR112014019825B1 (pt) | 2012-02-10 | 2013-02-11 | Glicoengenharia quimioenzimática de anticorpos e fragmentos fc dos mesmos |
Country Status (9)
Country | Link |
---|---|
US (5) | US9434786B2 (pt) |
EP (1) | EP2812442B9 (pt) |
JP (1) | JP6282232B2 (pt) |
CN (1) | CN104220603B (pt) |
BR (1) | BR112014019825B1 (pt) |
CA (1) | CA2862925C (pt) |
IL (1) | IL233779B (pt) |
IN (1) | IN2014DN06806A (pt) |
WO (1) | WO2013120066A1 (pt) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
EP2318832B1 (en) | 2008-07-15 | 2013-10-09 | Academia Sinica | Glycan arrays on ptfe-like aluminum coated glass slides and related methods |
US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
WO2011130332A1 (en) | 2010-04-12 | 2011-10-20 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
CA2835489C (en) | 2010-05-10 | 2018-03-06 | Chi-Huey Wong | Zanamivir phosphonate congeners with anti-influenza activity and determining oseltamivir susceptibility of influenza viruses |
US9175326B2 (en) * | 2011-03-03 | 2015-11-03 | University Of Maryland, Baltimore | Transglycosylation activity of glycosynthase mutants of an endo-beta-N-acetylglucosaminidase (endo-D) from streptococcus pneumoniae |
BR112014019825B1 (pt) * | 2012-02-10 | 2021-08-24 | University Of Maryland, Baltimore | Glicoengenharia quimioenzimática de anticorpos e fragmentos fc dos mesmos |
US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
AU2013306098A1 (en) | 2012-08-18 | 2015-02-12 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
WO2014031762A1 (en) | 2012-08-21 | 2014-02-27 | Academia Sinica | Benzocyclooctyne compounds and uses thereof |
ES2759503T3 (es) | 2013-05-02 | 2020-05-11 | Glykos Finland Oy | Conjugados de una glicoproteína o un glicano con una carga útil tóxica |
WO2014186310A1 (en) | 2013-05-13 | 2014-11-20 | Momenta Pharmaceuticals, Inc. | Methods for the treatment of neurodegeneration |
US10086054B2 (en) | 2013-06-26 | 2018-10-02 | Academia Sinica | RM2 antigens and use thereof |
WO2014210564A1 (en) | 2013-06-27 | 2014-12-31 | Academia Sinica | Glycan conjugates and use thereof |
WO2015032899A1 (en) * | 2013-09-05 | 2015-03-12 | Vib Vzw | Cells producing fc containing molecules having altered glycosylation patterns and methods and use thereof |
US9782476B2 (en) | 2013-09-06 | 2017-10-10 | Academia Sinica | Human iNKT cell activation using glycolipids with altered glycosyl groups |
WO2015057622A1 (en) | 2013-10-16 | 2015-04-23 | Momenta Pharmaceuticals, Inc. | Sialylated glycoproteins |
KR102311761B1 (ko) * | 2013-12-09 | 2021-10-13 | 알라코스 인크. | 항-Siglec-8 항체 및 그의 사용 방법 |
US9689016B2 (en) | 2013-12-18 | 2017-06-27 | Caliber Biotherapeutics, Llc | Method for in vivo production of deglycosylated recombinant proteins used as substrate for downstream protein glycoremodeling |
PL406737A1 (pl) * | 2013-12-31 | 2015-07-06 | Michał Lower | Sposób przemysłowego wytwarzania białek terapeutycznych o pożądanym profilu glikozylacji |
EP3094352B1 (en) | 2014-01-16 | 2020-09-23 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
TWI682033B (zh) | 2014-03-17 | 2020-01-11 | 泉盛生物科技股份有限公司 | 製造具有經修飾的糖苷化作用之重組糖蛋白之方法 |
WO2015148915A1 (en) | 2014-03-27 | 2015-10-01 | Academia Sinica | Reactive labelling compounds and uses thereof |
JP6750148B2 (ja) * | 2014-04-25 | 2020-09-02 | 公益財団法人野口研究所 | 糖鎖切断抗体の製造方法及び均一糖鎖抗体 |
KR20220151036A (ko) * | 2014-05-27 | 2022-11-11 | 아카데미아 시니카 | 항-cd20 글리코항체 및 이의 용도 |
US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
AU2015267045B2 (en) | 2014-05-27 | 2021-02-25 | Academia Sinica | Anti-HER2 glycoantibodies and uses thereof |
CA2950577A1 (en) * | 2014-05-27 | 2015-12-03 | Academia Sinica | Fucosidase from bacteroides and methods using the same |
KR102494193B1 (ko) * | 2014-05-28 | 2023-01-31 | 아카데미아 시니카 | 항-tnf-알파 글리코항체 및 이의 용도 |
EP3191500A4 (en) | 2014-09-08 | 2018-04-11 | Academia Sinica | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS |
US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
EP3248005B1 (en) | 2015-01-24 | 2020-12-09 | Academia Sinica | Novel glycan conjugates and methods of use thereof |
CN107614521B (zh) * | 2015-01-30 | 2022-02-08 | 台湾地区“中央研究院” | 增进抗体功效的通用糖型组合物及方法 |
JP6830576B2 (ja) * | 2015-02-26 | 2021-02-17 | 東京化成工業株式会社 | エンドm変異体、及びn結合型糖鎖含有化合物又はn結合型糖鎖含有蛋白質の製造方法 |
JP6744738B2 (ja) * | 2015-06-29 | 2020-08-19 | 公益財団法人野口研究所 | グライコシンターゼ |
JP6752203B2 (ja) * | 2015-07-16 | 2020-09-09 | 第一三共株式会社 | 新規EndoS変異酵素 |
WO2017018474A1 (ja) * | 2015-07-29 | 2017-02-02 | 公益財団法人野口研究所 | コアフコース含有抗体の調製方法 |
US10935544B2 (en) | 2015-09-04 | 2021-03-02 | Obi Pharma, Inc. | Glycan arrays and method of use |
CN105277718B (zh) * | 2015-09-29 | 2018-03-20 | 上海知先生物科技有限公司 | 用于恶性肿瘤相关筛查及评估的产品、应用及方法 |
JP6618176B2 (ja) * | 2015-11-30 | 2019-12-11 | 公益財団法人野口研究所 | 7糖オリゴ糖の製造方法 |
JP2019501663A (ja) * | 2016-01-15 | 2019-01-24 | ユニバーシティー オブ メリーランド,カレッジ パーク | グリコシンターゼとしてのEndo−S2変異体、糖タンパク質の製造方法および糖タンパク質の糖鎖操作のための使用 |
WO2017156192A1 (en) | 2016-03-08 | 2017-09-14 | Academia Sinica | Methods for modular synthesis of n-glycans and arrays thereof |
BR112018070097A2 (pt) | 2016-03-29 | 2019-02-12 | Obi Pharma, Inc. | anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos |
US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
EP3445395A4 (en) | 2016-04-22 | 2019-12-25 | OBI Pharma, Inc. | ANTI-CANCER IMMUNOTHERAPY BY IMMUNO-ACTIVATION OR IMMUNOMODULATION THROUGH GLOBO SERIES ANTIGENS |
US11008392B2 (en) | 2016-07-01 | 2021-05-18 | Daiichi Sankyo Company, Limited | HANP-Fc-containing molecular conjugate |
TWI786054B (zh) | 2016-07-29 | 2022-12-11 | 台灣浩鼎生技股份有限公司 | 人類抗體、醫藥組合物、及其方法 |
JP6731381B2 (ja) * | 2016-08-10 | 2020-07-29 | 公益財団法人野口研究所 | ポリエチレングリコール鎖が導入された化合物の製造方法 |
WO2018031734A1 (en) | 2016-08-10 | 2018-02-15 | University Of Maryland, College Park | DESIGNER α1,6-FUCOSIDASE MUTANTS ENABLE DIRECT CORE FUCOSYLATION OF INTACT N-GLYCOPEPTIDES AND N-GLYCOPROTEINS |
CN107778372B (zh) * | 2016-08-22 | 2019-11-26 | 中国科学院上海药物研究所 | 一种寡糖连接子以及利用该寡糖连接子制备的定点连接的抗体-药物偶联物 |
CN109963868B (zh) | 2016-08-22 | 2023-11-14 | 醣基生医股份有限公司 | 抗体、结合片段及使用方法 |
CA3034876C (en) * | 2016-08-24 | 2022-10-04 | CHO Pharma Inc. | Endoglycosidase mutants for glycoprotein remodeling and methods of using it |
EP3559249A1 (en) | 2016-12-21 | 2019-10-30 | H. Hoffnabb-La Roche Ag | Method for in vitro glycoengineering of antibodies |
CN110088291A (zh) * | 2016-12-21 | 2019-08-02 | 豪夫迈·罗氏有限公司 | 用于体外糖工程化抗体的方法 |
CN106596827B (zh) * | 2017-01-23 | 2019-06-07 | 上海知先生物科技有限公司 | Gal指标在自身免疫疾病治疗敏感性和疗效评估中的应用 |
JP2020518638A (ja) | 2017-05-05 | 2020-06-25 | アラコス インコーポレイテッド | アレルギー性眼疾患を処置するための方法および組成物 |
US10836815B2 (en) | 2017-06-29 | 2020-11-17 | University Of Maryland, College Park | Generation and comparative kinetic analysis of new glycosynthase mutants from Streptococcus pyogenes endoglycosidases for antibody glycoengineering |
TW202404648A (zh) | 2017-09-29 | 2024-02-01 | 日商第一三共股份有限公司 | 抗體-吡咯并苯二氮呯衍生物複合體 |
SG11202010939WA (en) | 2018-05-31 | 2020-12-30 | Daiichi Sankyo Co Ltd | Anti-human tlr7 antibody |
TW202035444A (zh) * | 2018-06-27 | 2020-10-01 | 台灣浩鼎生技股份有限公司 | 用於糖蛋白工程的糖苷合成酶變體及其使用方法 |
SG11202100947SA (en) | 2018-07-31 | 2021-03-30 | Daiichi Sankyo Co Ltd | Treatment of metastatic brain tumor by administration of antibody-drug conjugate |
JP7458981B2 (ja) | 2018-08-06 | 2024-04-01 | 第一三共株式会社 | 抗体-薬物コンジュゲートとチューブリン阻害剤の組み合わせ |
CA3113207A1 (en) | 2018-09-20 | 2020-03-26 | Daiichi Sankyo Company, Limited | Treatment of her3-mutated cancer by administration of anti-her3 antibody-drug conjugate |
CN113166764A (zh) | 2018-11-14 | 2021-07-23 | 第一三共株式会社 | 抗cdh6抗体-吡咯并苯并二氮杂环庚三烯衍生物缀合物 |
AU2019396895A1 (en) | 2018-12-11 | 2021-07-08 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate with PARP inhibitor |
US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
BR112021017616A2 (pt) | 2019-03-25 | 2021-11-09 | Daiichi Sankyo Co Ltd | Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina |
WO2020196474A1 (ja) | 2019-03-25 | 2020-10-01 | 第一三共株式会社 | 抗体-ピロロベンゾジアゼピン誘導体コンジュゲート |
JPWO2020196712A1 (pt) | 2019-03-27 | 2020-10-01 | ||
KR20220025721A (ko) * | 2019-08-05 | 2022-03-03 | 초 파마 인크. | 항체 글리코폼을 리모델링하기 위한 융합 단백질 |
US20230039189A1 (en) * | 2020-01-10 | 2023-02-09 | Riken | Population of antibodies comprising homogeneous antibodies each having left-right asymmetric sugar chains, and method for producing same |
CN115943157A (zh) | 2020-01-21 | 2023-04-07 | 耶路撒冷希伯来大学伊森姆研究发展公司 | 植物蛋白质同源物在培养基中的利用 |
CN116194109A (zh) | 2020-06-24 | 2023-05-30 | 阿斯利康(英国)有限公司 | 抗体-药物缀合物和atm抑制剂的组合 |
WO2021260582A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and aurora b inhibitor |
IL299368A (en) | 2020-06-24 | 2023-02-01 | Astrazeneca Uk Ltd | A combination of an antibody-drug conjugate and an ATR inhibitor |
WO2021260583A1 (en) | 2020-06-24 | 2021-12-30 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and dna-pk inhibitor |
TW202216207A (zh) | 2020-06-24 | 2022-05-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及cdk9抑制劑之組合 |
TW202227479A (zh) | 2020-09-02 | 2022-07-16 | 日商第一三共股份有限公司 | 新穎內-β-N-乙醯葡萄糖胺苷酶 |
AU2021356762A1 (en) | 2020-10-09 | 2023-05-25 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and parp1 selective inhibitor |
JPWO2022102634A1 (pt) | 2020-11-11 | 2022-05-19 | ||
CA3198382A1 (en) | 2020-11-12 | 2022-05-19 | Michiko Yamato | Treatment of mesothelioma by administration of anti-b7-h3 antibody-drug conjugate |
CN112442124B (zh) * | 2020-12-09 | 2022-01-14 | 福州迈新生物技术开发有限公司 | 抗cd23蛋白单克隆抗体、细胞系及其制备方法和应用 |
WO2022153194A1 (en) | 2021-01-13 | 2022-07-21 | Memorial Sloan Kettering Cancer Center | Antibody-pyrrolobenzodiazepine derivative conjugate |
JPWO2022211075A1 (pt) | 2021-03-31 | 2022-10-06 | ||
AU2022289365A1 (en) * | 2021-06-07 | 2023-12-14 | Amgen Inc. | Using fucosidase to control afucosylation level of glycosylated proteins |
TW202330041A (zh) | 2021-10-18 | 2023-08-01 | 日商第一三共股份有限公司 | 抗cd37抗體-藥物結合物 |
CN113960232B (zh) * | 2021-10-28 | 2024-02-20 | 苏州大学 | 一种基于唾液特异性岩藻糖基化结构糖谱及其检测方法和应用 |
TW202329936A (zh) | 2021-11-18 | 2023-08-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物與parp1選擇性抑制劑之組合 |
TW202339805A (zh) | 2021-12-28 | 2023-10-16 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及atr抑制劑之組合 |
TW202333800A (zh) | 2021-12-28 | 2023-09-01 | 英商阿斯特捷利康英國股份有限公司 | 抗體-藥物結合物及rasg12c抑制劑之組合 |
WO2023175483A1 (en) | 2022-03-16 | 2023-09-21 | Astrazeneca Uk Limited | A scoring method for an anti-trop2 antibody‑drug conjugate therapy |
TW202400140A (zh) | 2022-04-27 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合 |
TW202400650A (zh) | 2022-05-11 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體與cd47抑制劑之組合 |
WO2024002330A1 (zh) * | 2022-07-01 | 2024-01-04 | 启德医药科技(苏州)有限公司 | 固定化的内切糖苷酶融合蛋白及其应用 |
WO2024023750A1 (en) | 2022-07-28 | 2024-02-01 | Astrazeneca Uk Limited | Combination of antibody-drug conjugate and bispecific checkpoint inhibitor |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH072895A (ja) * | 1993-04-28 | 1995-01-06 | Eli Lilly & Co | 抗体−薬物複合体 |
JP2005535280A (ja) | 2001-11-28 | 2005-11-24 | ネオーズ テクノロジーズ, インコーポレイテッド | エンドグリカナーゼを用いる糖タンパク質のリモデリング |
WO2004000802A2 (en) | 2002-06-20 | 2003-12-31 | University Of Maryland Biotechnology Institute | Scaffolded maleimide clusters for multivalent peptide assembly |
EP1572963A4 (en) | 2002-10-11 | 2007-08-22 | Univ Maryland Biotech Inst | SYNTHETIC VACCINES CARBOHYDRATE BASE AGAINST HIV |
US20050064540A1 (en) | 2002-11-27 | 2005-03-24 | Defrees Shawn Ph.D | Glycoprotein remodeling using endoglycanases |
US7604804B2 (en) | 2004-02-09 | 2009-10-20 | University Of Maryland Biotechnology Institute | Enhancing anti-HIV efficiency through multivalent inhibitors targeting oligomeric gp120 |
US7728106B2 (en) | 2005-07-01 | 2010-06-01 | University Of Maryland Biotechnology Institute | HIV-1 glycopeptides and derivatives; preparation and applications thereof |
US20100221241A1 (en) | 2005-07-06 | 2010-09-02 | University Of Maryland Biotechnology Institute | Constrained hiv envelope-based immunogen that simultaneously presents receptor and coreceptor binding sites |
EP1937308A4 (en) | 2005-09-14 | 2010-09-15 | Univ Maryland Biotech Inst | SYNTHETIC ADDED CARBOHYDRATES AS INGREDIENTS OF MICROBICIDES |
AU2006312148B2 (en) | 2005-11-07 | 2012-04-12 | The Rockefeller University | Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof |
WO2007133855A2 (en) | 2006-03-27 | 2007-11-22 | University Of Maryland Biotechnology Institute | Glycoprotein synthesis and remodeling by enzymatic transglycosylation |
EP2029159A2 (en) * | 2006-06-06 | 2009-03-04 | Genentech, Inc. | Compositions and methods for modulating vascular development |
WO2007146847A2 (en) | 2006-06-09 | 2007-12-21 | University Of Maryland, Baltimore | Glycosylation engineered antibody therapy |
GB0624874D0 (en) * | 2006-12-13 | 2007-01-24 | Hansa Medical Ab | Treatment |
CN101889082A (zh) | 2007-09-14 | 2010-11-17 | 季诺维斯公司 | 用于解离Fcgamma-受体-IgG复合物以及纯化与检测IgG的方法和试剂盒 |
GB0821100D0 (en) | 2008-11-18 | 2008-12-24 | Hansa Medical Ab | Antibodies |
ES2528321T3 (es) | 2009-10-02 | 2015-02-06 | Roche Glycart Ag | Detección de a-fucosilación en anticuerpos |
CN102770554B (zh) | 2009-10-29 | 2016-02-17 | 詹森生物科技公司 | 抗体糖基化变体 |
US10087236B2 (en) * | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
US10851174B2 (en) | 2011-03-03 | 2020-12-01 | University Of Maryland, Baltimore | Core fucosylated glycopeptides and glycoproteins: chemoenzymatic synthesis and uses thereof |
BR112014019825B1 (pt) * | 2012-02-10 | 2021-08-24 | University Of Maryland, Baltimore | Glicoengenharia quimioenzimática de anticorpos e fragmentos fc dos mesmos |
-
2013
- 2013-02-11 BR BR112014019825-0A patent/BR112014019825B1/pt active IP Right Grant
- 2013-02-11 EP EP13746579.5A patent/EP2812442B9/en active Active
- 2013-02-11 IN IN6806DEN2014 patent/IN2014DN06806A/en unknown
- 2013-02-11 JP JP2014556776A patent/JP6282232B2/ja active Active
- 2013-02-11 WO PCT/US2013/025553 patent/WO2013120066A1/en active Application Filing
- 2013-02-11 US US14/376,248 patent/US9434786B2/en active Active
- 2013-02-11 CA CA2862925A patent/CA2862925C/en active Active
- 2013-02-11 CN CN201380008969.7A patent/CN104220603B/zh active Active
-
2014
- 2014-07-24 IL IL233779A patent/IL233779B/en active IP Right Grant
-
2016
- 2016-09-06 US US15/256,854 patent/US9845360B2/en active Active
-
2017
- 2017-12-15 US US15/843,160 patent/US10344063B2/en active Active
-
2019
- 2019-06-05 US US16/431,907 patent/US10836805B2/en active Active
-
2020
- 2020-11-13 US US17/097,534 patent/US11643450B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN104220603B (zh) | 2017-06-06 |
BR112014019825B1 (pt) | 2021-08-24 |
JP6282232B2 (ja) | 2018-02-21 |
IL233779A0 (en) | 2014-09-30 |
BR112014019825A2 (pt) | 2017-06-20 |
US20150087814A1 (en) | 2015-03-26 |
IN2014DN06806A (pt) | 2015-05-22 |
CA2862925A1 (en) | 2013-08-15 |
US10344063B2 (en) | 2019-07-09 |
EP2812442B9 (en) | 2023-02-15 |
EP2812442B1 (en) | 2022-11-30 |
JP2015507925A (ja) | 2015-03-16 |
US20190367570A1 (en) | 2019-12-05 |
CA2862925C (en) | 2020-01-21 |
US20170058040A1 (en) | 2017-03-02 |
US9845360B2 (en) | 2017-12-19 |
EP2812442A4 (en) | 2015-12-23 |
US20180186847A1 (en) | 2018-07-05 |
EP2812442A1 (en) | 2014-12-17 |
WO2013120066A1 (en) | 2013-08-15 |
US20210061868A1 (en) | 2021-03-04 |
IL233779B (en) | 2019-09-26 |
US9434786B2 (en) | 2016-09-06 |
US11643450B2 (en) | 2023-05-09 |
US10836805B2 (en) | 2020-11-17 |
CN104220603A (zh) | 2014-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112014019825A8 (pt) | Glicoengenharia quimioenzimática de anticorpos e fragmentos fc dos mesmos | |
BR112013020500A2 (pt) | anticorpo isolado, recombinante ou purificado | |
CL2013001471A1 (es) | Composicion que comprende al menos una n-acetil-lactosamina, al menos un oligosacarido sialilado y al menos un oligosacarido fucosilado y un hidrolizado que comprende proteinas parcialmente y/o completamente hidrolizadas; y su uso para la prevencion y/o tratamiento de las condiciones de la piel y enfermedades de la piel. | |
EA201490447A1 (ru) | Эндогликозидаза из streptococcus pyogenes и способы с применением указанной эндогликозидазы | |
BR112014026755A2 (pt) | anticorpos contra claudin 18.2 úteis no diagnóstico de câncer | |
BR112018003535A2 (pt) | receptor de antígeno quimérico, vetor de expressão, composição farmacêutica, e, uso de um vetor de expressão | |
BR112017023646A2 (pt) | proteínas agonistas de receptor de cd40 de cadeia simples | |
BR112016012860A2 (pt) | Compostos de biarila úteis no tratamento de doenças humanas em oncologia, neurologia e imunologia | |
MX363737B (es) | Mezcla de oligosacarido y producto alimenticio que comprende esta mezcla, especialmente una formula infantil. | |
ECSP12012140A (es) | Compuestos de para la inhibición de inmunoproteasomas | |
BRPI1012082A2 (pt) | composição aquosa , método para preparar um composição de igg concentrada a partir de plasma , e, uso da composição. | |
BR112012023910A2 (pt) | preparações cosméticas ou dermatológicas com um teor de um ou mais derivados de tiazol | |
BR112014004929A2 (pt) | conversão de unidades de alquilação de hf para processos de alquilação catalisada por líquido iônico | |
BR112014003477A2 (pt) | composições imunoterapêuticas de levedura-muc1 e usos das mesmas | |
BR112014002817A2 (pt) | Uso de um polipeptídeo p62, ou de um ácido nucleico que codifica p62 | |
BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab | |
CO6890074A2 (es) | Anticuerpos monoclonales frente al inhibidor de la ruta del factor tisular (tfpi) | |
EP2751675A4 (en) | DESCRIPTION OF NATIVE APPLICATION PROGRAMMING INTERFACES OF AN OPERATING SYSTEM WITH METADATA | |
BR112013007263A2 (pt) | desmanosilação de n-glicanos fosforilados | |
EA201591687A1 (ru) | Индукционная терапия ритуксимабом с последующим лечением с использованием глатирамера ацетата | |
BR112015021483A2 (pt) | arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer | |
BR112012027648A2 (pt) | composto medicamento, método para profilaxia ou tratamento de doença, e, uso de composto | |
BR112012019351A2 (pt) | composição de combinação, que inclui como ingredientes ativos l-carnitina ou propionil l-carnitina, para a prevenção ou tratamento de insuficiência venosa crônica. | |
BR112016014042A2 (pt) | composições e métodos para tratar deposição de tecido adiposo | |
BR112014007756A2 (pt) | sistema de fixação e segmento de correia transportadora |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06I | Publication of requirement cancelled [chapter 6.9 patent gazette] |
Free format text: ANULADA A PUBLICACAO CODIGO 6.21 NA RPI NO 2612 DE 26/01/2021 POR TER SIDO INDEVIDA. |
|
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/02/2013, OBSERVADAS AS CONDICOES LEGAIS. |